tldrdailynews.com logo

Novo Nordisk's Weight-Loss Drug Sales Surge, Stock Pops on Q4 Earnings Beat

1 min read
Source: Endpoints News
Novo Nordisk's Weight-Loss Drug Sales Surge, Stock Pops on Q4 Earnings Beat
Photo: Endpoints News
TL;DR

Novo Nordisk reports a 38% growth in demand for its GLP-1 products for diabetes and obesity, but continues to face supply issues with its drug Wegovy in the US due to unrelenting demand, with the FDA still listing it in shortage. The company has doubled its starter doses for Wegovy in the US, but CEO Lars Fruergaard Jørgensen acknowledges that supply will likely remain unsteady for some time due to overwhelming demand that outstrips production capacity.

Topics:businesshealthcare-pharmaceuticals#diabetes#healthcare-pharmaceuticals#novo-nordisk#obesity#supply-issues#wegovy
Share this article
  1. Novo Nordisk continues diabetes, obesity sales rise, but still on the back foot with Wegovy supply  Endpoints News
  2. Novo Nordisk hits $500 billion in market value as it flags soaring demand for Wegovy, Ozempic  CNBC
  3. Ozempic Maker Novo Nordisk Beats Profit Forecasts As Weight-Loss Sales Soar  Forbes
  4. Novo Nordisk Begins Gradually Increasing Supply of Blockbuster Weight-Loss Drug Wegovy  The Wall Street Journal
  5. Novo Nordisk stock pops on Q4 earnings beat  Yahoo Finance

Want the full story? Read the original reporting

Read on Endpoints News